Aims: Compare effects of liraglutide 1.8 mg and sulphonylurea, both combined with metformin, on glycaemic control in patients with type 2 diabetes (T2D) fasting during Ramadan. 
| INTRODUCTION
The month of Ramadan is observed as a period of fasting (i.e. abstention from eating, drinking and intake of oral medications) from dawn to sunset. Approximately 100 million of the worldwide 1.6 billion Muslim population have type 2 diabetes (T2D). 1, 2 Although the Quran 3 exempts certain patients with T2D from fasting, the EPIDIAR study, conducted in 13 countries, reported that 79% of patients with T2D fast during Ramadan despite an increased risk of acute complications. 4 The CREED study reported that 64% of patients with T2D fasted every day of Ramadan and 94.2% fasted for at least 15 days. 2 American Diabetes Association (ADA) recommendations for the management of T2D during Ramadan focus on the importance of preparation by undergoing medical assessment, education regarding hypoglycaemia prevention during fasting and individual guidance 1-2 months prior to Ramadan. 5, 6 The Ramadan Education and Awareness in Diabetes (READ) programme demonstrated that individuals who attended education sessions lost more weight and experienced fewer hypoglycaemic episodes than those not attending. 7 Metformin is generally considered a safe treatment during Ramadan. 6 Sulphonylureas, especially glyburide and glibenclamide, should be used with caution because of the inherent risk of hypoglycaemia, increased during fasting. 5, 6 Recent guidelines for T2D management during Ramadan indicate that further studies investigating the use of sulphonylureas are still required. 5 Sulphonylureas and metformin represent the treatment of choice in South
Asia for T2D management because of the large body of clinical evidence, as well as their availability and low cost. 8 Incretin-based therapy may be an alternative to sulphonylureas for T2D management during Ramadan because of the inherent low risk of hypoglycaemia. There have been several observational and interventional trials investigating the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors when used during Ramadan. [9] [10] [11] By contrast, limited clinical data exist on the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs)
when used during Ramadan. Therefore, studies are warranted to provide more informed decisions about choosing glucose-lowering treatments for patients with T2D intending to fast during Ramadan.
GLP-1RAs lower blood glucose by stimulating insulin and reducing glucagon secretion, both in a glucose-dependent manner in relation to elevated glucose levels. [12] [13] [14] [15] Liraglutide is an injectable, once-daily GLP-1 analogue administered subcutaneously. 16, 17 Liraglutide has a well-characterized safety profile, with the most frequently reported adverse events being gastrointestinal (i.e. nausea, vomiting and diarrhoea) during treatment initiation. Liraglutide is associated with a low risk of hypoglycaemia, which, in addition to its beneficial effect on glycaemic control and body weight, makes it potentially attractive as a glucose-lowering treatment during Ramadan.
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The LIRA-Ramadan trial (ClinicalTrials.gov, NCT01917656) was conducted to compare the effect of liraglutide versus sulphonylurea, both combined with metformin, on change in glycaemic control during Ramadan fasting in patients with T2D.
| MATERIALS AND METHODS

| Study design and participants
This randomized, parallel, open-label, active-controlled trial was conducted at 39 sites in 7 countries (see File S1). The 33-week trial consisted of a screening period (2 weeks) followed by dose escalation for the liraglutide group (3-4 weeks), a treatment maintenance period (6-19 weeks), the Ramadan treatment period (4 weeks), a post-Ramadan treatment period (4 weeks) and follow-up (1 week) ( Figure S1 , File S1).
The flexible duration of the treatment maintenance period (6-19 weeks) was to ensure recruitment of all patients prior to Ramadan. Patients had to be enrolled ≥10 weeks and ≤22 weeks prior to Ramadan. 
| Procedures
Assessments were conducted at the following timepoints:
• Fructosamine: baseline, beginning and end of Ramadan.
• Fasting plasma glucose (FPG): baseline, beginning and end of Ramadan and end of treatment (EoT).
• HbA1c , body weight, systolic (SBP) and diastolic (DBP) blood pressure: screening, baseline, beginning and end of Ramadan and EoT.
Subjects were to record in the patient diary fasting self-measured plasma glucose (SMPG), using the plasma glucose (PG) meter provided, on a weekly basis or more frequently at the investigator's discretion. If any fasting SMPG measurement met the limits of unacceptable hyperglycaemia (see File S1, withdrawal criteria), the subject was to contact the investigator. Treatment-emergent adverse events (TEAEs) and hypoglycaemic episodes were assessed at all phone contacts and site visits.
| Endpoints
The primary endpoint was change in fructosamine level from the beginning to the end of Ramadan. Fructosamine, which measures glycated serum proteins, is a validated marker of short-term (2-4 weeks) glycaemic control. 
| Statistical analysis
Using a standard two-sided t-test, the sample size of 160 patients/ arm to be randomized provided 90% power to detect a difference of between treatments in HbA1c. 27 In addition, the following were The demographic and baseline characteristics were well balanced between groups (Table 1) .
Dosing adjustments were reported in nine subjects (6.0%) in the liraglutide group and 48 subjects (29.1%) in the sulphonylurea group during Ramadan; these are shown in File S1.
| Results from the beginning to the end of Ramadan
The primary endpoint was change in fructosamine level from the beginning to end of Ramadan ( Figure 1A) . Figure 2B . Within the sulphonylurea strata, more subjects in the glibenclamide/glyburide stratum (14.8%, 4/27 subjects) experienced ADA-classified documented hypoglycaemic episodes than in the glimepiride/gliclazide/glipizide stratum (9.8%, 14/143 subjects) ( Figure S4 , File S1. No confirmed nocturnal hypoglycaemic episodes were reported with liraglutide; two episodes were reported by two subjects with sulphonylurea. From baseline to EoT, fewer hypoglycaemic episodes classified according to ADA definitions were reported with liraglutide (17.0%, 29 subjects, 944 episodes/1000 PYE) than with sulphonylurea (32.4%, 55 subjects, 2622 episodes/1000 PYE) ( Figure S5 , File S1). 26 The proportion of subjects with confirmed hypoglycaemic episodes with liraglutide (2.9%, 5 subjects, 88 episodes/1000 PYE) was lower than with sulphonylurea (9.4%, 16 subjects, 393 episodes/1000 PYE)
with an estimated rate ratio (liraglutide/sulphonylurea) of confirmed From baseline to EoT, the proportion of subjects reporting TEAEs and the event rate were greater with liraglutide (76.6%; 8584 events/1000 PYE) than with sulphonylurea (57.1%; 3084 events/ 1000 PYE) (Table S2 , File S1). Most subjects had recovered by the end of the trial. There was a low incidence of SAEs (liraglutide 2.9%; sulphonylurea 1.2%). Only liraglutide-treated subjects (11%; 6.4%) experienced TEAEs that led to withdrawal. No fatal events or cases of acute or chronic pancreatitis were reported.
| DISCUSSION
Fasting during Ramadan is an important spiritual practice, and some patients with diabetes fast despite being at high risk of complications. 2 Ramadan fasting implies major changes in dietary habits for patients with T2D and is a challenge, as it may require changes in glucose-lowering medication. In LIRA-Ramadan, despite better glycaemic control in the liraglutide group at the beginning of Ramadan, similar glycaemic improvements were achieved during Ramadan with liraglutide and sulphonylurea, with comparable reductions in fructosamine levels.
Despite lower levels of fructosamine and HbA1c during Ramadan, the risk of ADA-documented symptomatic hypoglycaemic episodes during Ramadan was significantly lower with liraglutide versus sulphonylurea. For subjects randomized to sulphonylurea, more subjects in the glibenclamide/glyburide stratum experienced ADA-classified hypoglycaemic episodes than those in the glimepiride/gliclazide/glipizide stratum, as previously reported. 5, 29 Glibenclamide/glyburide may be associated with a higher risk of hypoglycaemia than other secondgeneration sulphonylureas, specifically gliclazide, glimepiride and glipizide. 29, 30 Gliclazide, previously shown to have a low hypoglycaemia rate during Ramadan, was the most frequently used sulphonylurea in this trial. 10 Importantly, however, it seems the lower risk of ADAdocumented symptomatic hypoglycaemic episodes with liraglutide versus sulphonylurea applied to all the second-generation sulphonylureas used in this trial. Risks of ADA-classified documented symptomatic hypoglycaemia and confirmed hypoglycaemia were also significantly lower for liraglutide versus sulphonylurea in the overall trial period.
Body weight and SBP decreased significantly during Ramadan and from baseline to end of Ramadan with liraglutide versus sulphonylurea.
The clinical significance of these results is underlined by the significantly higher proportion of patients in the liraglutide groups achieving HbA1c <7.0% (53 mmol/mol), HbA1c <7.0% (53 mmol/mol) and no confirmed hypoglycaemia, and HbA1c <7.0% (53 mmol/mol), no weight gain and no confirmed hypoglycaemia at the end of Ramadan.
Although a similar number of patients withdrew from each group after randomization, the timing of and reasons for withdrawal were different. More patients treated with liraglutide than with sulphonylurea withdrew prior to Ramadan, primarily because of gastrointestinal AEs, with half of these occurring during dose escalation.
However, during Ramadan, more patients taking sulphonylurea withdrew, mostly because of lack of efficacy. Therefore, it is recommended to complete dose escalation of liraglutide at least 6-8 weeks prior to Ramadan, as in this trial. No patients withdrew because of AEs during Ramadan. AEs, adverse events; E, number of events; N, number of subjects; R, event rate/1000 patient-years of exposure; TEAE, treatment-emergent adverse event. for sulphonylureas administered at higher than half the maximum approved dose, the glucose-lowering effect levels off as the dose increases. 35 However, theoretically, if the physician had chosen to increase the dose of sulphonylurea for patients on a dose lower than the maximum approved dose, the hypoglycaemia rate in the sulphonylurea group would probably have been higher during Ramadan. During
Ramadan, reducing the dose of sulphonylurea and/or adjusting timing of administration was allowed, according to ADA recommendations. 5 Most changes to the dose regimen in sulphonylurea treatment were related to dose reduction, although splitting the dose or changing the timing of the dose was also reported. There were very few changes to the dose of liraglutide during Ramadan (nine patients, of whom eight received a reduced dose), with almost all patients being maintained at the maximum dose of 1.8 mg. There were few patients reporting changes in metformin treatment; similar in both arms (nine and eight in the liraglutide and sulphonylurea arms, respectively). It should be emphasized that this was a switch trial (i.e. subjects randomized to liraglutide had pre-trial sulphonylurea replaced by liraglutide at baseline).
In summary, despite lower fructosamine levels and lower HbA1c at the start of Ramadan, liraglutide-treated subjects were able to fast and experienced similar glycaemic improvement compared to sulphonylurea-treated subjects, with fewer hypoglycaemic episodes despite better glycaemic control. Thus, liraglutide is an effective, well-tolerated and safe choice when used as glucose-lowering therapy in patients with T2D who choose to fast during Ramadan. 
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